The world says ‘NamAIste' to Made in India's world's first Hospitality GPT by IIHM

AI-powered knowledge engine built on deep domain research is the global hospitality industry's biggest innovation. Hospitality stakeholders and industry captains hail the launch of 'NamAIste – IIHM Hospitality GPT' as a Viksit Bharat enterprise.
KOLKATA, India , May 25, 2025 /PRNewswire/ — There is a new dawn in the world of hospitality. The global unison of technology and human touch, in the form of the world's first-ever hospitality-exclusive GPT, was launched in Kolkata, India , following the vision of Prime Minister Narendra Modi's dream for a 'Make in India ' technology in the spirit of Viksit Bharat.
Pioneered by the visionary zeal of AI evangelist and Chairman of IIHM, Dr. Suborno Bose, the NamAIste IIHM Hospitality GPT was introduced and launched, before a global audience of hospitality leaders, students, and stakeholders, as a vehicle of limitless possibilities. NamAIste – HospitalityGPT is the world's first Generative AI-powered knowledge engine tailored for the hospitality industry.
Beyond the realms of a chatbot or a normal GPT, the 'NamAIste – IIHM Hospitality GPT' is a repository of extensive, inclusive, and exclusive knowledge, information, research, innovation, and trends which will be galaxies beyond what a normal search engine or chatbot can do.
This was welcomed by the industry as nothing less than a giant satellite launch into space. In effect, it wasn't far from that, as the NamAIste IIHM Hospitality GPT will traverse new horizons, giving closed-user access to information and research that will be unmatched.
Proudly Made in India , Made by Indians, NamAIste is a customized Large Language Model (LLM) specifically engineered for the hospitality sector. It empowers AI-driven learning, decision-making, and innovation—ushering in a new era of hospitality intelligence.
As the creator of NamAIste IIHM Hospitality GPT, Dr. Suborno Bose, Chairman, IIHM, said,
'The industry is ready to accept it. The industry is waiting. It's a global mind changer. It is not just a tech marvel but a dawn of a new way of thinking and the dawn of reimagining things.'
During his vision address at the grand launch event at IIHM Global Campus—and joined virtually from India and nations across time zones and geographies—Dr. Suborno Bose said,
'It is an engine of innovation, excellence, and a bold announcement that India is at par with the best in the world. The time for India to lead has come — and we have arrived. If the US can have Google, and China can have DeepSeek, India can — and now does — have NamAIste. NamAIste – IIHM HospitalityGPT is designed to empower students, faculty, hospitality professionals, and industry stakeholders with real-time access to insights, trends, and global best practices.'
Entiovi Technologies was the tech partner of the project that developed NamAIste, a customized Large Language Model (LLM) specifically tailored for the hospitality industry—ensuring hospitality-centric AI-powered learning and decision-making. Sanjoy Chatterjee , Director, Entiovi Technologies, an industry-admired name in tech innovation, said during his vision address,
'It all started with an early morning conversation between me and Dr. Bose in February this year. The uniqueness of NamAIste is not technology. The whole platform is built on open-source technology. The uniqueness is creating the knowledge base from 60 countries. Imagine a student in Bengal writing a question about Japanese culinary history and the answer coming from Japanese documents in Bengali.'
When this was demonstrated, the entire audience in Kolkata and those who participated virtually burst into loud applause. Countries across the world also realised the depth and uniqueness of this exclusive knowledge.
Dr. Suborno Bose then went on to underline the significance of this global launch to the country,
'I must congratulate team IIHM and Entiovi Technologies but especially our country India , our Viksit Bharat. This is a true Make in India moment because it shows what we are capable of and this is for the entire hospitality industry which has been a huge supporter of IIHM for 34 years. This is what our mission statement is all about—innovation and creativity. This is another great example of how IIHM comes out of the traditional hospitality education to innovative education backed by AI and tech emergence,' Dr. Bose added.
He added a sensitive human touch to the proceedings when he said,
'AI cannot change the human factor. Our industry is a people industry. It's for the people. This will always remain an industry of smiles and hospitable character. AI will assist this to ensure that we rise to the customer's expectations purposefully and work and apply AI in a different way.'
On how this hospitality GPT is for the future, Dr. Bose said,
'It is best for the students and will change the way hospitality education would be taught in the future. It's made by Indians, for the world. It's a gift from India to the world of hospitality. We do not teach our students hospitality management. We teach them the business of hospitality. We invest a lot to promote that.'
This was indeed a 'Greeted in India ' moment. As IIHM campuses across India erupted with joy and elation at the unlocking of limitless possibilities, students, faculty, and faculty members expressed pride in their institution that went beyond preparing students for hospitality, to creating an exclusive launch vehicle for global hospitality excellence. Made right at their home and made for the world.
Key Benefits of NamAIste: Revolutionizing hospitality education and training
Enabling smart, data-driven decision-making for industry professionals
Providing instant access to best practices, SOPs, and service innovation strategies
The launch was joined by hospitality educators, iconic chefs, CEOs of hospitality-linked companies, all of whom will be ambassadors taking the world of NamAIste IIHM Hospitality GPT to the world, for the students, innovators, and hospitality captains.
Manish Dayya , General Manager of Sofitel, BKC Mumbai, said elatedly,
'It is a proud moment for India as this tool is made in India and supports the Make in India movement. This tool and technology will support the hospitality industry in India and globally.'
Ishan Sarkar , Chief Business Officer, Indya Foods , commented,
'An evangelist is someone who brings good news. Dr. Suborno Bose is not just an AI evangelist—he is a hospitality evangelist. NamAIste is the best news the hospitality industry has received in the modern era.'
Sabrina Dey , General Manager, ITC Windsor, Bengaluru, said,
'The NamAIste – IIHM Hospitality GPT is truly a gift. Not only to India , but to the global hospitality community. If 'Tech and Touch' is the mantra, and integrating AI into hospitality is the goal, then NamAIste is the perfect launch vehicle. In the world of AI, this is nothing short of a space mission—turning the seemingly impossible into reality. Congratulations to Dr. Suborno Bose and the entire IIHM team.'
Every time this first-ever knowledge repository is opened anywhere in the world, the early morning conversation between Suborno Bose and Sanjoy Chatterjee , the visionary and creator, will ring somewhere in the hospitality ecosystem.
This is IIHM's gift to the global hospitality industry — and to hospitality students everywhere.
Logo – https://mma.prnewswire.com/media/2569189/IIHM_Logo.jpg
Photo – https://mma.prnewswire.com/media/2695627/IIHM_NamAIste.jpg

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

傳蘋果將捨棄Google合作 將收購AI搜尋黑馬Perplexity

科技中心／李宜樺報導 ▼▲蘋果傳新併購消息！恐捨棄Google，轉密會AI搜尋新星Perplexity。（圖／翻攝自YT@Apple） AI戰升溫，科技巨頭火力全開！繼Meta投資Scale AI後，如今傳出蘋果也悄悄布局，要收購AI搜尋新貴「Perplexity AI」，甚至傳出考慮放棄Google作為預設搜尋引擎。這場看似平靜的搜尋戰場，已悄然掀起風暴！ 根據《彭博》知名科技記者Mark Gurman爆料，蘋果併購部門主管Adrian Perica已在內部討論是否收購Perplexity，雖仍處於早期階段，但若交易成真，將是蘋果史上最大規模併購案──該公司估值高達140億美元，遠超2014年30億美元收購Beats的紀錄。 除了併購，蘋果也考慮另一合作模式，將Perplexity整合至Safari與Siri，作為替代Google搜尋的AI解決方案。畢竟蘋果與Google的搜尋合作協議，正面臨美國反壟斷調查威脅，恐有被迫拆夥的可能。 Perplexity成立僅兩年，卻以AI驅動搜尋技術嶄露頭角，透過自動總結、引文標示等功能挑戰Google霸主地位，甚至已與三星展開深度合作，成為蘋果收購計畫的潛在障礙。 Perplexity對收購傳聞低調回應，稱「目前沒有相關消息」，但該公司近期與多家科技巨頭接觸頻繁，包括Meta也曾試圖收購、並挖角其CEO Aravind Srinivas，顯示AI搜尋市場人才爭奪戰已進入白熱化。 當AI搜尋成為下一代搜尋引擎的競爭主戰場，蘋果此舉無疑是對Google發出重大威脅。科技巨頭的版圖重組已開始，誰能掌握搜尋流量與AI技術，誰就能主宰未來。 更多三立新聞網報導2025報稅必知／報稅倒數9天 你真的報完了嗎？「這一步」沒做＝白報！美軍參戰 介入以伊戰爭！衝突升級 冷靜異常的黃金現補漲行情？全球熱錢瘋搶亞洲 高盛曝對沖基金5年最大買盤新光金、新壽5月再虧破百億 靠準備金撐盤仍難止血？

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc.

Yahoo

an hour ago

• Yahoo

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory Verdine. The parties intend to execute a definitive agreement shortly. Under the collaboration, XtalPi will leverage its end-to-end, AI and robotics-driven platform to discover and develop small molecule and antibody drug candidates for multiple DoveTree-selected targets addressing oncology, autoimmune disorders, and neurological diseases. Pursuant to the LOI, XtalPi will receive an upfront payment of $51 million within 10 days of executing the definitive agreement and an additional $49 million within 180 days. Subject to final agreement terms, XtalPi is also eligible to receive potential development and commercial milestone payments exceeding $10 billion, as well as tiered, single-digit royalties on annual net product sales. DoveTree will obtain exclusive global development and commercialization rights to the resulting therapeutics. Professor Gregory Verdine, the Erving Professor of Chemistry at Harvard University, is a pioneer in chemical biology and a distinguished serial entrepreneur. Appointed to Harvard's faculty at age 29, he became the Chemistry Department's youngest tenured professor in nearly five decades at 35. He has elucidated the molecular mechanism of epigenetic DNA methylation and revealed the pathways by which certain genotoxic forms of DNA damage are identified and eradicated. He is a leading figure in the field of new therapeutic modalities, and has developed of a new class of therapeutics termed stapled peptides, enabling drug development against targets long considered undruggable. As an entrepreneurial leader, Professor Verdine has founded or co-founded over ten biotechnology companies, including five publicly listed entities: Enanta Pharmaceuticals (NASDAQ: ENTA), Tokai Pharmaceuticals (NASDAQ: TKAI), and Wave Life Sciences (NASDAQ: WVE), among others. One venture was acquired by a major pharmaceutical company, while others continue developing disruptive medicines with a special focus on oncology. Three therapeutics he spearheaded—romidepsin (Istodax®), paritaprevir (a component of Viekira Pak®), and glecaprevir (a component of Mavyret®) —have received FDA approval. Professor Verdine currently serves as a Venture Partner at Andreessen Horowitz (a16z), a role he previously held at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures. He was also a Special Advisor to Texas Pacific Group. His advisory engagements include top research institutions such as the U.S. National Cancer Institute and Harvard Medical School. "By integrating XtalPi's cutting-edge AI capabilities with decades of drug development expertise, we have a unique opportunity to deliver transformative therapies to patients worldwide," stated Professor Verdine. About XtalPi XtalPi Holdings Limited (XtalPi, was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries. View original content to download multimedia: SOURCE XtalPi Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data